drugset / Trial / NCT03803163
A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers
NaSingle-groupOpen-labelOther
Summary
To determine the maximum tolerated dose (MTD) and assess safety and tolerability of escalating single doses of TransCon PEG treprostinil administered as a subcutaneous injection to healthy male volunteers.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-06
- Completion
- 2015-06
Outcome
Outcome not reported
Stopped: “Discontinued early due to local tolerance expectations not being met.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TransCon Treprostinil | Unknown | — | Subcutaneous |
Indications
No indication recorded.